-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b ...
– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell ...
The human body’s CD47 protein is a key cellular signaling molecule whose overexpression has been found to be correlated with poor prognosis in multiple cancer types, including acute myeloid leukemia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results